Form 8-K ZAFGEN, INC. For: Oct 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Zafgen (ZFGN) PT Cut to $46 at Leerink Partners Amid Partial Clinical Hold; Maintains Bullish View
October 16, 2015 12:07 PM EDTLeerink Partners analyst Joseph Schwartz lowered his price target on Zafgen (NASDAQ: ZFGN) to $46.00 (from $56.00) after the company announced that it received verbal notice from FDA late yesterday that beloranib has been placed on 'partial clinical hold.' However, the analyst is maintaining an Outperform... More
